Blood, serum and plasma represent accessible sources of data about physiological and pathological status. In Arrhythmogenic Cardiomyopathy (ACM), circulating nucleated cells are routinely employed for detection of germinal genetic mutations. In addition, different biomarkers have been proposed for diagnostic purposes and for monitoring disease progression, and these include inflammatory cytokines, markers of myocardial dysfunction and damage, microRNAs. This review summarizes the current information that can be retrieved from the blood of ACM patients and consider the future prospects. Improvements of current knowledge about circulating factors may provide non-invasive means to simplify and improve the diagnosis, prognosis prediction and management of ACM patients.
Stadiotti I, Pompilio G, Maione AS, Pilato CA, D'Alessandra Y, Sommariva E. Arrhythmogenic Cardiomyopathy: what blood can reveal? Heart Rhythm 2018 Sep 26. pii: S1547-5271(18)30950-0. doi: 10.1016/j.hrthm.2018.09.023. [Epub ahead of print]